Based on a phase I/II clinical trial (NCT01915498), enasidenib (Idhifa®) was approved by the FDA on 1 August 2017, for the treatment of adult patients with relapsed or refractory AML with an IDH2 mutation [345]. This evidence concerns the gene IDH2 and acute myeloid leukemia.